Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Change in Receivables (2016 - 2025)

Abeona Therapeutics has reported Change in Receivables over the past 14 years, most recently at -$1.0 million for Q4 2025.

  • Quarterly results put Change in Receivables at -$1.0 million for Q4 2025, down 2787.18% from a year ago — trailing twelve months through Dec 2025 was -$1.1 million (down 36.87% YoY), and the annual figure for FY2025 was -$1.1 million, down 36.87%.
  • Change in Receivables for Q4 2025 was -$1.0 million at Abeona Therapeutics, down from -$14000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for ABEO hit a ceiling of $3.4 million in Q2 2023 and a floor of -$3.0 million in Q1 2022.
  • Median Change in Receivables over the past 4 years was -$20500.0 (2024), compared with a mean of $22062.5.
  • Biggest five-year swings in Change in Receivables: surged 242.5% in 2023 and later crashed 2787.18% in 2025.
  • Abeona Therapeutics' Change in Receivables stood at -$859000.0 in 2022, then surged by 102.33% to $20000.0 in 2023, then soared by 95.0% to $39000.0 in 2024, then crashed by 2787.18% to -$1.0 million in 2025.
  • The last three reported values for Change in Receivables were -$1.0 million (Q4 2025), -$14000.0 (Q3 2025), and $13000.0 (Q2 2025) per Business Quant data.